Stephen T Oh

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6493887/publications.pdf

Version: 2024-02-01

89 papers	3,829 citations	304743 22 h-index	133252 59 g-index
105 all docs	105 docs citations	105 times ranked	6101 citing authors

#	Article	IF	Citations
1	Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. Haematologica, 2022, 107, 1599-1607.	3.5	27
2	Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFÎºB pathway inhibition. Blood Advances, 2022, 6, 611-623.	5.2	11
3	Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib. British Journal of Haematology, 2022, 197, .	2.5	8
4	CLO22-067: Symptom Burden in Patients With Myelofibrosis who Have Moderate or Severe Thrombocytopenia: A Retrospective Analysis of Patients Enrolled in the PERSIST-2 Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, CLO22-067.	4.9	0
5	Momelotinib reduces transfusion requirements in patients with myelofibrosis. Leukemia and Lymphoma, 2022, 63, 1718-1722.	1.3	8
6	Toll-like receptor and cytokine expression throughout the bone marrow differs between patients with low- and high-risk myelodysplastic syndromes. Experimental Hematology, 2022, 110, 47-59.	0.4	7
7	Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer, 2022, 128, 2420-2432.	4.1	24
8	Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF).. Journal of Clinical Oncology, 2022, 40, 7058-7058.	1.6	3
9	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncology, 2021, 17, 1449-1458.	2.4	31
10	Co-evolution of tumor and immune cells during progression of multiple myeloma. Nature Communications, 2021, 12, 2559.	12.8	68
11	Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.. Journal of Clinical Oncology, 2021, 39, e19040-e19040.	1.6	0
12	A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms. Cancer Discovery, 2021, 11, 3126-3141.	9.4	17
13	Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry. JCI Insight, 2021, 6, .	5.0	10
14	Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. JCO Precision Oncology, 2021, 5, 191-203.	3.0	4
15	A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia. Blood, 2021, 138, 3639-3639.	1.4	3
16	Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Commpass Study. Blood, 2021, 138, 2691-2691.	1.4	0
17	Evidence of NF-ÎšB Pathway Activation in Patients with Advanced, High Molecular Risk Myelofibrosis. Blood, 2021, 138, 3584-3584.	1.4	0
18	Baseline Serum Ferritin Differentially Predicts W24 Transfusion Independence Response for Momelotinib and Ruxolitinib in Patients with Myelofibrosis. Blood, 2021, 138, 3638-3638.	1.4	1

#	Article	IF	Citations
19	DUSP6 Mediates Resistance to JAK2 Inhibition and Drives Myeloproliferative Neoplasm Disease Progression. Blood, 2021, 138, 55-55.	1.4	1
20	Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3KÎ´ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF). Blood, 2021, 138, 3647-3647.	1.4	2
21	A Real-World Evaluation of the Association between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera (Analysis of Data from the REVEAL Study). Blood, 2021, 138, 239-239.	1.4	4
22	Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nature Medicine, 2021, 27, 2192-2199.	30.7	79
23	Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 219-225.	0.4	13
24	Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2020, 38, 1006-1018.	1.6	71
25	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Advances, 2020, 4, 4282-4291.	5.2	77
26	Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Advances, 2020, 4, 5825-5835.	5.2	60
27	Unraveling the Architecture of Classic Hodgkin Lymphoma One Cell at a Time. Cancer Discovery, 2020, 10, 342-344.	9.4	3
28	Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor NaÃ¯ve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients. Blood, 2020, 136, 51-52.	1.4	12
29	A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104). Blood, 2020, 136, 3-3.	1.4	3
30	Imaging Mass Cytometry Reveals the Spatial Architecture of Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemias. Blood, 2020, 136, 44-45.	1.4	2
31	STEM-17. NOT ALL GBM STEM CELLS ARE EQUAL: IMPLICATIONS FOR RESEARCH AND THERAPY. Neuro-Oncology, 2020, 22, ii199-ii200.	1.2	0
32	Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood, 2019, 134, 867-879.	1.4	55
33	147â€…Characterization of cell-bound complement activation products on SLE PBMCs using mass cytometry. , 2019, , .		0
34	Identification of functionally primitive and immunophenotypically distinct subpopulations in secondary acute myeloid leukemia by mass cytometry. Cytometry Part B - Clinical Cytometry, 2019, 96, 46-56.	1.5	16
35	Young versus old age at diagnosis confers distinct genomic profiles in patients with polycythemia vera. Leukemia, 2019, 33, 1522-1526.	7.2	7
36	Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFÎºB signaling. Leukemia, 2019, 33, 1978-1995.	7.2	94

#	Article	IF	Citations
37	Altered Dynamics of Monocyte Subpopulations and Pro-Inflammatory Signaling Pathways in Polycythemia Vera Revealed By Mass Cytometry. Blood, 2019, 134, 4210-4210.	1.4	2
38	Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages. Blood, 2019, 134, 364-364.	1.4	0
39	Interrogating the Role of ASXL1 and JAK2 mutations in Myeloproliferative Neoplasms Utilizing Human Pluripotent Stem Cells. Blood, 2019, 134, 2971-2971.	1.4	0
40	Interrogating the Spatial Architecture of Human Bone Marrow Via Imaging Mass Cytometry. Blood, 2019, 134, 3728-3728.	1.4	0
41	Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib. Blood, 2019, 134, 4214-4214.	1.4	1
42	Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic veinÂthrombosis. British Journal of Haematology, 2018, 183, 310-313.	2.5	24
43	Myeloid/lymphoid neoplasms withFGFR1rearrangement. Leukemia and Lymphoma, 2018, 59, 1672-1676.	1.3	53
44	JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells. Cancer Cell, 2018, 34, 741-756.e8.	16.8	44
45	Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 788-795.e2.	0.4	19
46	A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia. Cancer Research, 2018, 78, 6762-6770.	0.9	17
47	High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. Cell, 2018, 175, 1014-1030.e19.	28.9	292
48	Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 590-596.	0.4	22
49	Identification of enhanced IFN-Î³ signaling in polyarticular juvenile idiopathic arthritis with mass cytometry. JCI Insight, 2018, 3, .	5.0	22
50	A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3KÎ´ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis. Blood, 2018, 132, 353-353.	1.4	13
51	Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients. Blood, 2018, 132, 4282-4282.	1.4	7
52	Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia. Blood, 2018, 132, 350-350.	1.4	5
53	Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFÎºB Signaling. Blood, 2018, 132, 3062-3062.	1.4	0
54	Young Versus Old Age at Diagnosis Confers Distinct Genomic Profiles in Patients with Polycythemia Vera. Blood, 2018, 132, 4322-4322.	1.4	0

#	Article	IF	Citations
55	Hepcidin Is Elevated in Primary and Secondary Myelofibrosis and Correlates with IL-6 and IL-2RÎ± but Is High in Patients Treated with Ruxolitinib. Blood, 2018, 132, 1760-1760.	1.4	4
56	A phase 2 study of simtuzumab in patients with primary, postâ€polycythaemia vera or postâ€essential thrombocythaemia myelofibrosis. British Journal of Haematology, 2017, 176, 939-949.	2.5	40
57	Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease. Therapeutic Advances in Hematology, 2017, 8, 107-118.	2.5	40
58	Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature. Current Hematologic Malignancy Reports, 2017, 12, 397-405.	2.3	9
59	Analysis of Signaling Networks at the Single-Cell Level Using Mass Cytometry. Methods in Molecular Biology, 2017, 1636, 371-392.	0.9	19
60	Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS ONE, 2017, 12, e0179558.	2.5	41
61	Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia. New England Journal of Medicine, 2016, 375, 494-496.	27.0	21
62	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 2016, 375, 2023-2036.	27.0	663
63	Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Science Translational Medicine, 2016, 8, 357ra123.	12.4	621
64	Concurrent MPL W515L and Y591D mutations in a patient with myelofibrosis. Blood Cells, Molecules, and Diseases, 2016, 60, 1-2.	1.4	1
65	Examining the Clinical Features and Underlying Cardiovascular Risk Among Patients with Polycythemia Vera in the REVEAL Study. Blood, 2016, 128, 1934-1934.	1.4	1
66	Mass Cytometry Analysis of Dysregulated Cytokine Production and Intracellular Signaling in Myelofibrosis. Blood, 2016, 128, 4277-4277.	1.4	1
67	Distinct Clinical, Laboratory, and Molecular Features of Myeloproliferative Neoplasm Patients Presenting with Splanchnic Vein Thrombosis. Blood, 2016, 128, 3121-3121.	1.4	1
68	A Novel CSF3R Mutation Uncovers the Importance of Membrane-Proximal N-Glycosylation for Receptor Regulation. Blood, 2016, 128, 3141-3141.	1.4	0
69	Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 424-434.	4.9	24
70	Brief Report: Chikungunya Viral Arthritis in the United States: A Mimic of Seronegative Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 1214-1220.	5.6	122
71	Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. Journal of Clinical Oncology, 2015, 33, 3953-3960.	1.6	69
72	NF Kappa B Signaling Hyperactivation in Myelofibrosis and Secondary Acute Myeloid Leukemia. Blood, 2015, 126, 602-602.	1.4	1

#	Article	IF	Citations
73	Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. Blood, 2015, 126, 689-689.	1.4	1
74	A Phase 2 Study to Evaluate the Efficacy and Safety of Simtuzumab in Adult Subjects with Primary, Post Polycythemia Vera (PV) or Post Essential Thrombocythemia (ET) Myelofibrosis. Blood, 2015, 126, 2810-2810.	1.4	0
75	Prognostication in MF: From CBC to cytogenetics to molecular markers. Best Practice and Research in Clinical Haematology, 2014, 27, 155-164.	1.7	8
76	Clinical Significance of LNK (SH2B3) Expression in Pediatric B Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3772-3772.	1.4	0
77	Single Cell Mass Cytometry Reveals Hyperactivated Signaling Networks in Myeloproliferative Neoplasms. Blood, 2014, 124, 1884-1884.	1.4	2
78	OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML. New England Journal of Medicine, 2013, 368, 1781-1790.	27.0	499
79	The JAK Inhibitor Ruxolitinib Elicits Hematologic and Symptomatic Improvement In Patients With Chuvash Polycythemia. Blood, 2013, 122, 4051-4051.	1.4	3
80	Mass Cytometry Analysis Of Myelofibrosis and Secondary Acute Myeloid Leukemia Reveals Constitutive and Cytokine Induced Signaling Abnormalities With Differential Sensitivities To Ruxolitinib. Blood, 2013, 122, 1610-1610.	1.4	9
81	The CSF3R T618I Mutation Found In Chronic Neutrophilic Leukemia Removes An O-Linked Glycosylation Site and Increases Receptor Dimerization. Blood, 2013, 122, 270-270.	1.4	0
82	Concomitant JAK2 V617F-Positive Polycythemia Vera and BCR-ABL-Positive Chronic Myelogenous Leukemia Treated with Ruxolitinib and Dasatinib.. Blood, 2012, 120, 2832-2832.	1.4	1
83	Single Cell Mass Cytometry of Dysregulated Signaling Networks in Myeloproliferative Neoplasms and Secondary Acute Myeloid Leukemia. Blood, 2012, 120, 703-703.	1.4	1
84	Clonal Evolution Revealed by Whole Genome Sequencing in a Case of Primary Myelofibrosis Transformed to Secondary Acute Myeloid Leukemia. Blood, 2012, 120, 706-706.	1.4	1
85	Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood, 2010, 116, 988-992.	1.4	295
86	JAK2V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Review of Hematology, 2010, 3, 323-337.	2.2	73
87	Identification of a Novel Splice Donor Mutation In the Thrombopoietin Gene In a Philippine Family with Hereditary Thrombocythemia. Blood, 2010, 116, 3086-3086.	1.4	1
88	Identification of Novel LNK Mutations In Patients with Chronic Myeloproliferative Neoplasms and Related Disorders. Blood, 2010, 116, 315-315.	1.4	7
89	Antiangiogenic therapy in myelodysplastic syndromes: Is there a role?. Current Hematologic Malignancy Reports, 2008, 3, 10-18.	2.3	2